Ampion is a non-steroidal anti inflammatory drug indicated for treatment in the homeostasis of inflammation.
During the course of the study, twenty patients were randomized to receive either intranasal Ampion, or saline, twice a day during a 10 day double-blind period which followed a one week washout period.
The subjects reported reflective total nasal symptom scores (rTNSS) as well as instantaneous total nasal symptom scores (iTNSS) every 12 hours.
The trial demonstrated an improvement in rTNSS in the intranasal Ampion group over the saline group.